H1 IPO
H1 operates a global healthcare network and data platform that connects healthcare professionals with life sciences companies for research, clinical trials, and medical affairs activities. The company has raised substantial venture funding and serves major pharmaceutical and biotech companies, positioning it as a potential player in the growing healthcare technology IPO market.
Key Facts
| Industry | Healthcare Data Intelligence |
| Founded | 2020 |
| Headquarters | New York, NY |
| Employees | ~800 |
| Website | h1co.com |
| Funding | Series C at $1.8B valuation. Total raised: ~$240M |
About H1
H1 operates a healthcare data intelligence platform that maps and analyzes the global healthcare ecosystem, focusing on healthcare professional (HCP) data and research insights. The company maintains one of the world's largest databases of healthcare professionals, including detailed profiles of doctors, researchers, and medical institutions. H1's platform serves pharmaceutical companies, medical device manufacturers, and healthcare organizations by providing insights for clinical trial recruitment, medical affairs strategies, and market research.
The company's technology uses artificial intelligence to analyze medical literature, clinical trial data, and professional networks to identify key opinion leaders and research trends in specific therapeutic areas. H1's platform is particularly valuable for life sciences companies looking to identify the right healthcare professionals for clinical advisory roles, speaker programs, or research collaborations. The company has built comprehensive coverage across multiple countries and therapeutic areas, making it a critical tool for global pharmaceutical companies' commercial and research operations.
IPO Status
H1 has not made any public announcements regarding an initial public offering. The healthcare data platform, which has raised significant venture capital funding in recent years, continues to operate as a private company while expanding its global network of healthcare professionals. The company has shown strong growth in serving pharmaceutical and biotech companies' needs for expert networks and clinical trial recruitment. However, there have been no confirmed reports or official communications about IPO plans or timeline from the company's leadership.
Competitors
Frequently Asked Questions
Does H1 have a stock?
No, H1 has not had an IPO. The company remains privately held with no announced plans to go public.
When is the H1 IPO date?
H1 has not announced an IPO date. There are no confirmed details about potential public offering timing.
How can I buy H1 stock?
H1 stock is not available for purchase as the company is privately held. Shares would become available through brokers if they go public in the future.
Stay Updated on the H1 IPO
Get real-time alerts when H1 files for an IPO, prices shares, or begins trading.
Get IPO Alerts